-
Loading metrics
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
- Ranjan Chrisanthar,
- Stian Knappskog,
- Erik Løkkevik,
- Gun Anker,
- Bjørn Østenstad,
- Steinar Lundgren,
- Terje Risberg,
- Ingvil Mjaaland,
- Gudbrand Skjønsberg,
- Turid Aas
x
- Published: April 27, 2011
- https://doi.org/10.1371/journal.pone.0019249